Lexeo Therapeutics, Inc. Variable Lease, Cost
Lexeo Therapeutics, Inc. (LXEO) reported Variable Lease, Cost of $128.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-12
- Lexeo Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $128.00K, a 1.59% increase year-over-year.
- Lexeo Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $131.00K, a 3.97% increase year-over-year.
- Lexeo Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $126.00K, a 9.57% increase year-over-year.
- Lexeo Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $126.00K, a 8.62% increase year-over-year.
- Lexeo Therapeutics, Inc. variable lease, cost for fiscal 2025 was $503.00K, a 9.59% increase from fiscal 2024.
- Lexeo Therapeutics, Inc. variable lease, cost for fiscal 2024 was $459.00K, a 29.30% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. variable lease, cost for fiscal 2023 was $355.00K, a 91.89% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. variable lease, cost for fiscal 2022 was $185.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 9 month as first filed | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $128.00K 10-Q · filed 2026-08-12 | $259.00K 10-Q · filed 2026-08-12 | $385.00K derived: sum of 3 quarters · filed 2026-08-12 | $511.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $131.00K 10-Q · filed 2026-05-11 | $257.00K derived: sum of 2 quarters · filed 2026-05-11 | $383.00K derived: sum of 3 quarters · filed 2026-05-11 | $509.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $252.00K derived: sum of 2 quarters · filed 2026-03-30 | $378.00K derived: sum of 3 quarters · filed 2026-08-12 | $503.00K 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $126.00K 10-Q · filed 2025-11-05 | $252.00K derived: sum of 2 quarters · filed 2026-08-12 | $377.00K 10-Q · filed 2025-11-05 | $493.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $126.00K 10-Q · filed 2026-08-12 | $252.00K 10-Q · filed 2026-08-12 | $367.00K derived: sum of 3 quarters · filed 2026-08-12 | $483.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $126.00K 10-Q · filed 2026-05-11 | $241.00K derived: sum of 2 quarters · filed 2026-05-11 | $357.00K derived: sum of 3 quarters · filed 2026-05-11 | $472.00K derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $231.00K derived: sum of 2 quarters · filed 2026-03-30 | $346.00K derived: sum of 3 quarters · filed 2026-03-30 | $459.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $116.00K 10-Q · filed 2025-11-05 | $231.00K derived: sum of 2 quarters · filed 2025-11-05 | $344.00K 10-Q · filed 2025-11-05 | $210.00K derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $115.00K 10-Q · filed 2025-08-14 | $228.00K 10-Q · filed 2025-08-14 | $94.00K derived: sum of 3 quarters · filed 2025-08-14 | $389.00K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $113.00K 10-Q · filed 2025-05-12 | -$21.00K derived: sum of 2 quarters · filed 2025-05-12 | $274.00K derived: sum of 3 quarters · filed 2025-05-12 | $399.00K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $161.00K derived: sum of 2 quarters · filed 2025-03-24 | $286.00K derived: sum of 3 quarters · filed 2025-03-24 | $355.00K 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $295.00K 10-Q · filed 2024-11-13 | $78.00K 10-Q · filed 2023-12-11 | $420.00K derived: sum of 2 quarters · filed 2024-11-13 | $489.00K 10-Q · filed 2024-11-13 | $226.00K 10-Q · filed 2023-12-11 | $535.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $125.00K 10-Q · filed 2024-08-12 | $194.00K 10-Q · filed 2024-08-12 | $240.00K derived: sum of 3 quarters · filed 2024-08-12 | $309.00K derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $69.00K 10-Q · filed 2024-05-09 | $115.00K derived: sum of 2 quarters · filed 2024-05-09 | $184.00K derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $115.00K derived: sum of 2 quarters · filed 2024-03-11 | $185.00K 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $69.00K 10-Q · filed 2023-12-11 | $139.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |